110 related articles for article (PubMed ID: 8971086)
1. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies.
Desideri G; Ferri C; Bellini C; De Mattia G; Santucci A
Diabetes; 1997 Jan; 46(1):81-6. PubMed ID: 8971086
[TBL] [Abstract][Full Text] [Related]
2. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin.
Momose N; Fukuo K; Morimoto S; Ogihara T
Hypertension; 1993 Jun; 21(6 Pt 2):921-4. PubMed ID: 8389325
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries.
Gauthier KM; Cepura CJ; Campbell WB
Biol Chem; 2013 Sep; 394(9):1205-12. PubMed ID: 23729620
[TBL] [Abstract][Full Text] [Related]
4. Cocaine-stimulated endothelin-1 release is decreased by angiotensin-converting enzyme inhibitors in cultured endothelial cells.
Hendricks-Munoz KD; Gerrets RP; Higgins RD; Munoz JL; Caines VV
Cardiovasc Res; 1996 Jan; 31(1):117-23. PubMed ID: 8849595
[TBL] [Abstract][Full Text] [Related]
5. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: bradykinin may improve insulin resistance in dogs and humans.
Uehara M; Kishikawa H; Isami S; Kisanuki K; Ohkubo Y; Miyamura N; Miyata T; Yano T; Shichiri M
Diabetologia; 1994 Mar; 37(3):300-7. PubMed ID: 8174845
[TBL] [Abstract][Full Text] [Related]
6. Converting enzyme inhibitor-stimulated formation of nitric oxide and prostacyclin in endothelial cells from bovine aorta is mediated by endothelium-derived bradykinin.
Wiemer G; Schölkens BA; Becker RH
Agents Actions Suppl; 1992; 38 ( Pt 3)():196-200. PubMed ID: 1334350
[TBL] [Abstract][Full Text] [Related]
7. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism.
Zanzinger J; Zheng X; Bassenge E
Cardiovasc Res; 1994 Feb; 28(2):209-14. PubMed ID: 8143302
[TBL] [Abstract][Full Text] [Related]
8. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals.
Leyva F; Wingrove C; Felton C; Stevenson JC
Metabolism; 1997 Oct; 46(10):1137-9. PubMed ID: 9322795
[TBL] [Abstract][Full Text] [Related]
9. Hyperoxia stimulates endothelin-1 secretion from endothelial cells; modulation by captopril and nifedipine.
Higgins RD; Hendricks-Munoz KD; Caines VV; Gerrets RP; Rifkin DB
Curr Eye Res; 1998 May; 17(5):487-93. PubMed ID: 9617543
[TBL] [Abstract][Full Text] [Related]
10. Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats.
Damas J; Hallet C; Lefebvre PJ
Br J Pharmacol; 2001 Nov; 134(6):1312-8. PubMed ID: 11704652
[TBL] [Abstract][Full Text] [Related]
11. Inhibition by angiotensin converting enzyme inhibitors of endothelin secretion from cultured human endothelial cells.
Yoshida H; Nakamura M
Life Sci; 1992; 50(22):PL195-200. PubMed ID: 1316980
[TBL] [Abstract][Full Text] [Related]
12. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells.
Maes W; Van Camp J; Vermeirssen V; Hemeryck M; Ketelslegers JM; Schrezenmeir J; Van Oostveldt P; Huyghebaert A
Regul Pept; 2004 Apr; 118(1-2):105-9. PubMed ID: 14759563
[TBL] [Abstract][Full Text] [Related]
13. ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.
Henriksen EJ; Jacob S; Kinnick TR; Youngblood EB; Schmit MB; Dietze GJ
Am J Physiol; 1999 Jul; 277(1):R332-6. PubMed ID: 10409290
[TBL] [Abstract][Full Text] [Related]
14. Captopril reverses the reduced vasodilator response to bradykinin in hypertensive pregnant rats.
Resende AC; Pimentel AM; de Moura RS
Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):756-61. PubMed ID: 15566389
[TBL] [Abstract][Full Text] [Related]
15. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway.
Desideri G; Grassi D; Croce G; Bocale R; Tiberti S; Evangelista S; Necozione S; Di Orio F; Ferri C
Mediators Inflamm; 2008; 2008():305087. PubMed ID: 19079593
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo.
Brouwers S; Smolders I; Massie A; Dupont AG
Hypertension; 2013 Nov; 62(5):920-6. PubMed ID: 24041944
[TBL] [Abstract][Full Text] [Related]
17. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
[TBL] [Abstract][Full Text] [Related]
18. A bradykinin antagonist abolishes beneficial effect of captopril on duration of survival after acute coronary artery ligation in hypertensive rats.
Sharma JN; Abbas SA
Pharmacol Res; 2005 Sep; 52(3):211-5. PubMed ID: 16026715
[TBL] [Abstract][Full Text] [Related]
19. NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss.
Nevelsteen I; Van den Bergh A; Van der Mieren G; Vanderper A; Mubagwa K; Bult H; Herijgers P
J Vasc Res; 2013; 50(6):486-97. PubMed ID: 24192582
[TBL] [Abstract][Full Text] [Related]
20. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Napoli C; Sica V; de Nigris F; Pignalosa O; Condorelli M; Ignarro LJ; Liguori A
Am Heart J; 2004 Jul; 148(1):e5. PubMed ID: 15215814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
